MAPT and dementia: Radiotracers targeting pathologic hallmarks of AD such as Aβ and tau proteins have allowed the differentiation of AD and non-AD dementia, the tracking of pathological protein burden over the temporal course of the disease, the stratification of patients for clinical trials, and the monitoring of biological effects of therapeutic agents.